Selected research
Industry Research
Neuromyelitis Optica Therapy Industry Research Report 2026
Market perspective
The global Neuromyelitis Optica Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neuromyelitis Optica Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neuromyelitis Optica Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neuromyelitis Optica Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neuromyelitis Optica Therapy include CBOP, CSL, Fresenius, Grifols, Gyjtrs, Intas, NANG KUANG, Octapharma and Tianjin Kingyork, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neuromyelitis Optica Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neuromyelitis Optica Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuromyelitis Optica Therapy Market by Company
CBOP
CSL
Fresenius
Grifols
Gyjtrs
Intas
NANG KUANG
Octapharma
Tianjin Kingyork
Baxter
Pfizer
Sandoz
Teva
Neuromyelitis Optica Therapy Segment by Type
Glucocorticoids
Immunotherapies
Other
Neuromyelitis Optica Therapy Segment by Application
Acute Attack
Remission Prophylactic Treatment
Neuromyelitis Optica Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neuromyelitis Optica Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Glucocorticoids
- Immunotherapies
- Other
Applications
- Acute Attack
- Remission Prophylactic Treatment
Companies covered
- CBOP
- CSL
- Fresenius
- Grifols
- Gyjtrs
- Intas
- NANG KUANG
- Octapharma
- Tianjin Kingyork
- Baxter
- Pfizer
- Sandoz
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neuromyelitis Optica Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Glucocorticoids
- 2.2.3 Immunotherapies
- 2.2.4 Other
- 2.3 Neuromyelitis Optica Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Acute Attack
- 2.3.3 Remission Prophylactic Treatment
- 2.4 Assumptions and Limitations
3 Neuromyelitis Optica Therapy Breakdown Data by Type
- 3.1 Global Neuromyelitis Optica Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Neuromyelitis Optica Therapy Forecasted Market Size by Type (2027-2032)
4 Neuromyelitis Optica Therapy Breakdown Data by Application
- 4.1 Global Neuromyelitis Optica Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Neuromyelitis Optica Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neuromyelitis Optica Therapy Market Perspective (2021-2032)
- 5.2 Global Neuromyelitis Optica Therapy Growth Trends by Region
- 5.2.1 Global Neuromyelitis Optica Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neuromyelitis Optica Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Neuromyelitis Optica Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Neuromyelitis Optica Therapy Market Dynamics
- 5.3.1 Neuromyelitis Optica Therapy Industry Trends
- 5.3.2 Neuromyelitis Optica Therapy Market Drivers
- 5.3.3 Neuromyelitis Optica Therapy Market Challenges
- 5.3.4 Neuromyelitis Optica Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neuromyelitis Optica Therapy Players by Revenue
- 6.1.1 Global Top Neuromyelitis Optica Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Neuromyelitis Optica Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Neuromyelitis Optica Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neuromyelitis Optica Therapy Head Office and Area Served
- 6.4 Global Neuromyelitis Optica Therapy Players, Product Type & Application
- 6.5 Global Neuromyelitis Optica Therapy Manufacturers Established Date
- 6.6 Global Neuromyelitis Optica Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neuromyelitis Optica Therapy Market Size (2021-2032)
- 7.2 North America Neuromyelitis Optica Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
- 7.4 North America Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neuromyelitis Optica Therapy Market Size (2021-2032)
- 8.2 Europe Neuromyelitis Optica Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
- 8.4 Europe Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neuromyelitis Optica Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Neuromyelitis Optica Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neuromyelitis Optica Therapy Market Size (2021-2032)
- 10.2 South America Neuromyelitis Optica Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
- 10.4 South America Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neuromyelitis Optica Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Neuromyelitis Optica Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 CBOP
- 12.1.1 CBOP Company Information
- 12.1.2 CBOP Business Overview
- 12.1.3 CBOP Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.1.4 CBOP Neuromyelitis Optica Therapy Product Portfolio
- 12.1.5 CBOP Recent Developments
- 12.2 CSL
- 12.2.1 CSL Company Information
- 12.2.2 CSL Business Overview
- 12.2.3 CSL Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.2.4 CSL Neuromyelitis Optica Therapy Product Portfolio
- 12.2.5 CSL Recent Developments
- 12.3 Fresenius
- 12.3.1 Fresenius Company Information
- 12.3.2 Fresenius Business Overview
- 12.3.3 Fresenius Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.3.4 Fresenius Neuromyelitis Optica Therapy Product Portfolio
- 12.3.5 Fresenius Recent Developments
- 12.4 Grifols
- 12.4.1 Grifols Company Information
- 12.4.2 Grifols Business Overview
- 12.4.3 Grifols Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.4.4 Grifols Neuromyelitis Optica Therapy Product Portfolio
- 12.4.5 Grifols Recent Developments
- 12.5 Gyjtrs
- 12.5.1 Gyjtrs Company Information
- 12.5.2 Gyjtrs Business Overview
- 12.5.3 Gyjtrs Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.5.4 Gyjtrs Neuromyelitis Optica Therapy Product Portfolio
- 12.5.5 Gyjtrs Recent Developments
- 12.6 Intas
- 12.6.1 Intas Company Information
- 12.6.2 Intas Business Overview
- 12.6.3 Intas Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.6.4 Intas Neuromyelitis Optica Therapy Product Portfolio
- 12.6.5 Intas Recent Developments
- 12.7 NANG KUANG
- 12.7.1 NANG KUANG Company Information
- 12.7.2 NANG KUANG Business Overview
- 12.7.3 NANG KUANG Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.7.4 NANG KUANG Neuromyelitis Optica Therapy Product Portfolio
- 12.7.5 NANG KUANG Recent Developments
- 12.8 Octapharma
- 12.8.1 Octapharma Company Information
- 12.8.2 Octapharma Business Overview
- 12.8.3 Octapharma Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.8.4 Octapharma Neuromyelitis Optica Therapy Product Portfolio
- 12.8.5 Octapharma Recent Developments
- 12.9 Tianjin Kingyork
- 12.9.1 Tianjin Kingyork Company Information
- 12.9.2 Tianjin Kingyork Business Overview
- 12.9.3 Tianjin Kingyork Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.9.4 Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio
- 12.9.5 Tianjin Kingyork Recent Developments
- 12.10 Baxter
- 12.10.1 Baxter Company Information
- 12.10.2 Baxter Business Overview
- 12.10.3 Baxter Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.10.4 Baxter Neuromyelitis Optica Therapy Product Portfolio
- 12.10.5 Baxter Recent Developments
- 12.11 Pfizer
- 12.11.1 Pfizer Company Information
- 12.11.2 Pfizer Business Overview
- 12.11.3 Pfizer Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.11.4 Pfizer Neuromyelitis Optica Therapy Product Portfolio
- 12.11.5 Pfizer Recent Developments
- 12.12 Sandoz
- 12.12.1 Sandoz Company Information
- 12.12.2 Sandoz Business Overview
- 12.12.3 Sandoz Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.12.4 Sandoz Neuromyelitis Optica Therapy Product Portfolio
- 12.12.5 Sandoz Recent Developments
- 12.13 Teva
- 12.13.1 Teva Company Information
- 12.13.2 Teva Business Overview
- 12.13.3 Teva Revenue in Neuromyelitis Optica Therapy Business (2021-2026)
- 12.13.4 Teva Neuromyelitis Optica Therapy Product Portfolio
- 12.13.5 Teva Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst